Sales results for DURAGESIC, a transdermal patch for chronic pain; ULTRACET, an analgesic; and SPORANOX, an antifungal, were all negatively impacted by generic competition.
Offsetting the impact of generic competition was the strong performance of RISPERDAL, an antipsychotic medication; REMICADE, a biologic approved for the treatment of a number of Immune Mediated Inflammatory Diseases; TOPAMAX, an antiepileptic and a treatment for the prevention of migraine headaches; and CONCERTA, a treatment for attention deficit hyperactivity disorder.
During the quarter, the European Commission granted marketing authorization in the 25 member states of the European Union for the use of IONSYS (fentanyl hydrochloride). IONSYS is the first needle-free, iontophoretic, patient-controlled transdermal system to receive marketing authorization. It is indicated for the management of acute moderate to severe post-operative pain, for use by adults, in a hospital setting.
On March 8, 2006, the Company announced that its Board of Directors approved a stock repurchase program, authorizing the Company to buy back up to $5 billion of the corporation's common stock.
Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. The more than 230 Johnson & Johnson operating companies employ approximately 116,000 men and women in 57 countries and sell products throughout the world.
marketing@alchempro.com
